|
[1]AGNELLO V, DE ROSA FG.Extrahepatic disease manifestations of HCV infection:Some current issues[J].J Hepatol, 2004, 40 (2) :341-352.
|
|
[2]BLACKARD JT, KEMMER N, SHERMAN KE.Extrahepatic replication of HCV:Insights into clinical manifestations and biological consequences[J].Hepatology, 2006, 44 (1) :15-22.
|
|
[3]FERRI C, RAMOS-CASALS M, ZIGNEGO AL, et al.International diagnostic guidelines for patients with HCV-related extrahepatic manifestations.A multidisciplinary expert statement[J].Autoimmun Rev, 2016, 15 (12) :1145-1160.
|
|
[4]ZIGNEGO AL, FERRI C, PILERI SA, et al.Extrahepatic manifestations of hepatitis C virus infection:A general overview and guidelines for a clinical approach[J].Dig Liver Dis, 2007, 39 (1) :2-17.
|
|
[5]YOUNOSSI Z, PARK H, HENRY L, et al.Extrahepatic manifestations of hepatitis C:A meta-analysis of prevalence, quality of life, and economic burden[J].Gastroenterology, 2016, 150 (7) :1599-1608.
|
|
[6]TIAN H.Extra-hepatic manifestions of HCV infection[J].Chin Hepatol, 2007, 12 (5) :408-411. (in Chinese) 田辉.HCV感染的肝外表现[J].肝脏, 2007, 12 (5) :408-411.
|
|
[7]SIAGRIS D, CHRISTOFIDOU M, TSAMANDAS A, et al.Cryoglobulinemia and progression of fibrosis in chronic HCV infection:Cause or effect?[J].J Infect, 2004, 49 (3) :236-241.
|
|
[8]KAYALI Z, BUCKWOLD VE, ZIMMERMAN B, et al.Hepatitis C, cryoglobulinemia, and cirrhosis:A meta-analysis[J].Hepatology, 2002, 36 (4 Pt 1) :978-985.
|
|
[9]de VITA S, SOLDANO F, ISOLA M, et al.Preliminary classification criteria for the cryoglobulinaemic vasculitis[J].Ann Rheum Dis, 2011, 70 (7) :1183-1190.
|
|
[10]SAADOUN D, RESCHE-RIGON M, THIBAULT V, et al.Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis:A long-term followup study[J].Arthritis Rheum, 2006, 54 (11) :3696-3706.
|
|
[11]GRAGNANI L, VISENTINI M, FOGNANI E, et al.Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia[J].Hepatology, 2016, 64 (5) :1473-1482.
|
|
[12]SANTER DM, MA MM, HOCKMAN D, et al.Enhanced activation of memory, but not na6ve, B cells in chronic hepatitis C virus-infected patients with cryoglobulinemia and advanced liver fibrosis[J].PLo S One, 2013, 8 (6) :e68308.
|
|
[13]NEGRO F, FORTON D, CRAXIA, et al.Extrahepatic morbidity and mortality of chronic hepatitis C[J].Gastroenterology, 2015, 149 (6) :1345-1360.
|
|
[14]de SANJOSE S, BENAVENTE Y, VAJDIC CM, et al.Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium[J].Clin Gastroenterol Hepatol, 2008, 6 (4) :451-458.
|
|
[15]OMATA M, KANDA T, YU ML, et al.APASL consensus statements and management algorithms for hepatitis C virus infection[J].Hepatol Int, 2012, 6 (2) :409-435.
|
|
[16]LODI G, PELLICANO R, CARROZZO M.Hepatitis C virus infection and lichen planus:A systematic review with meta-analysis[J].Oral Dis, 2010, 16 (7) :601-612.
|
|
[17]CARROZZO M, GANDOLFO S.Oral diseases possibly associated with hepatitis C virus[J].Crit Rev Oral Biol Med, 2003, 14 (2) :115-127.
|
|
[18]SAYINER M, GOLABI P, FARHAT F, et al.Dermatologic manifestations of chronic hepatitis C infection[J].Clin Liver Dis, 2017, 21 (3) :555-564.
|
|
[19]GISBERT JP, GARCIA-BUEY L, PAJARES JM, et al.Prevalence of hepatitis C virus infection in porphyria cutanea tarda:Systematic review and meta-analysis[J].J Hepatol, 2003, 39 (4) :620-627.
|
|
[20]AGUILERA P, LAGUNO M, TO-FIGUERAS J.Treatment of chronic hepatitis with boceprevir leads to remission of porphyria cutanea tarda[J].Br J Dermatol, 2014, 171 (6) :1595-1596.
|
|
[21]EL-SERAG HB, HAMPEL H, YEH C, et al.Extrahepatic manifestations of hepatitis C among United States male veterans[J].Hepatology, 2002, 36 (6) :1439-1445.
|
|
[22]JADALI Z.Dermatologic manifestations of hepatitis C infection and the effect of interferon therapy:A literature review[J].Arch Iran Med, 2012, 15 (1) :43-48.
|
|
[23]ALLISON ME, WREGHITT T, PALMER CR, et al.Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population[J].J Hepatol, 1994, 21 (6) :1135-1139.
|
|
[24]ANTONELLI A, FERRI C, FALLAHI P, et al.Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients[J].Rheumatology (Oxford) , 2004, 43 (2) :238-240.
|
|
[25]ANTONELLI A, FERRI C, FALLAHI P, et al.Hepatitis C virus infection:Evidence for an association with type 2 diabetes[J].Diabetes Care, 2005, 28 (10) :2548-2550.
|
|
[26]KONRAD T, ZEUZEM S, VICINI P, et al.Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha[J].Eur J Clin Invest, 2000, 30 (2) :111-121.
|
|
[27]CHEN CL, YANG HI, YANG WS, et al.Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection:A follow-up study in Taiwan[J].Gastroenterology, 2008, 135 (1) :111-121.
|
|
[28]SCHREUDER TC, GELDERBLOM HC, WEEGINK CJ, et al.High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection[J].Liver Int, 2008, 28 (1) :39-46.
|
|
[29]FIORINO S, BACCHI-REGGIANI L, de BIASE D, et al.Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma:A systematic review[J].World J Gastroenterol, 2015, 21 (45) :12896-12953.
|
|
[30]SEGNA D, DUFOUR JF.Other extrahepatic manifestations of hepatitis C virus infection (pulmonary, idiopathic thrombocytopenic purpura, nondiabetes endocrine disorders) [J].Clin Liver Dis, 2017, 21 (3) :607-629.
|
|
[31]TOMER Y, VILLANUEVA R.Hepatitis C and thyroid autoimmunity:Is there a link?[J].Am J Med, 2004, 117 (1) :60-61.
|
|
[32]TESTA A, CASTALDI P, FANT V, et al.Prevalence of HCV antibodies in autoimmune thyroid disease[J].Eur Rev Med Pharmacol Sci, 2006, 10 (4) :183-186.
|
|
[33]LUNEL F.Hepatitis C virus and autoimmunity:Fortuitous association or reality?[J].Gastroenterology, 1994, 107 (5) :1550-1555.
|
|
[34]PASTORE F, MARTOCCHIA A, STEFANELLI M, et al.Hepatitis C virus infection and thyroid autoimmune disorders:A model of interactions between the host and the environment[J].World J Hepatol, 2016, 8 (2) :83-91.
|
|
[35]BLACKARD JT, KONG L, HUBER AK, et al.Hepatitis C virus infection of a thyroid cell line:Implications for pathogenesis of hepatitis C virus and thyroiditis[J].Thyroid, 2013, 23 (7) :863-870.
|
|
[36]ROSENTHAL E, CACOUB P.Extrahepatic manifestations in chronic hepatitis C virus carriers[J].Lupus, 2015, 24 (4-5) :469-482.
|
|
[37]CACOUB P, RENOU C, ROSENTHAL E, et al.Extrahepatic manifestations associated with hepatitis C virus infection.A prospective multicenter study of 321 patients.The GERMIVIC.Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C[J].Medicine (Baltimore) , 2000, 79 (1) :47-56.
|
|
[38]ROSNER I, ROZENBAUM M, TOUBI E, et al.The case for hepatitis C arthritis[J].Semin Arthritis Rheum, 2004, 33 (6) :375-387.
|
|
[39]RAMOS-CASALS M, ZIGNEGO AL, FERRI C, et al.Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection[J].J Hepatol, 2017, 66 (6) :1282-1299.
|
|
[40]CACOUB P, COMARMOND C, DOMONT F, et al.Extrahepatic manifestations of chronic hepatitis C virus infection[J].Ther Adv Infect Dis, 2016, 3 (1) :3-14.
|
|
[41]CACOUB P, RATZIU V, MYERS RP, et al.Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C[J].J Hepatol, 2002, 36 (6) :812-818.
|
|
[42]Kidney Disease:Improving Global Outcomes (KDIGO) .KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease[J].Kidney Int Suppl, 2008, 109:s1-s99.
|
|
[43]DEGASPERI E, AGHEMO A, COLOMBO M.Treatment of extrahepatic manifestations of hepatitis C virus[J].Clin Liver Dis, 2017, 21 (3) :631-643.
|
|
[44]LU SY, RAO HY.Research advances in hepatitis C virus-related renal injury and its treatment[J].J Clin Hepatol, 2017, 33 (6) :1156-1160. (in Chinese) 卢淑媛, 饶慧瑛.HCV相关肾损伤及其治疗的研究进展[J].临床肝胆病杂志, 2017, 33 (6) :1156-1160.
|
|
[45] European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2016[J].J Hepatol, 2017, 66 (1) :153-194.
|
|
[46]LASKUS T, RADKOWSKI M, ADAIR DM, et al.Emerging evidence of hepatitis C virus neuroinvasion[J].AIDS, 2005, 19 (Suppl 3) :s140-s144.
|
|
[47]ADINOLFI LE, NEVOLA R, RINALDI L, et al.Chronic hepatitis C virus infection and depression[J].Clin Liver Dis, 2017, 21 (3) :517-534.
|
|
[48]IRIANA S, CURRY MP, AFDHAL NH.Neurologic manifestations of hepatitis C virus infection[J].Clin Liver Dis, 2017, 21 (3) :535-542.
|
|
[49]CACOUB P, GRAGNANI L, COMARMOND C, et al.Extrahepatic manifestations of chronic hepatitis C virus infection[J].Dig Liver Dis, 2014, 46 (Suppl 5) :s165-s173.
|
|
[50]GLEASON OC, YATES WR, ISBELL MD, et al.An open-label trial of citalopram for major depression in patients with hepatitis C[J].J Clin Psychiatry, 2002, 63 (3) :194-198.
|
|
[51]LEE MH, YANG HI, LU SN, et al.Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases:A community-based long-term prospective study[J].J Infect Dis, 2012, 206 (4) :469-477.
|
|
[52]GOOSSENS N, NEGRO F.Cardiovascular manifestations of hepatitis C virus[J].Clin Liver Dis, 2017, 21 (3) :465-473.
|
|
[53] GILL K, GHAZINIAN H, MANCH R, et al.Hepatitis C virus as a systemic disease:Reaching beyond the liver[J].Hepatol Int, 2016, 10 (3) :415-423.
|
|
[54]ALIANNEJAD R, GHANEI M.Hepatitis C and pulmonary fibrosis:Hepatitis C and pulmonary fibrosis[J].Hepat Mon, 2011, 11 (2) :71-73.
|
|
[55]ARASE Y, SUZUKI F, SUZUKI Y, et al.Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis[J].World J Gastroenterol, 2008, 14 (38) :5880-5886.
|
DownLoad: